Abstract 625P
Background
Tumor markers have been used for cancer screening and monitoring, yet their potential connection with air pollution remains largely unexplored. We aimed to examine the potential association between various air pollutants – including carbon monoxide (CO), nitrogen dioxide (NO2), sulfur dioxide (SO2), PM2.5, and PM10 – and the levels of tumor markers (AFP, CEA, CA19-9, CA125, and PSA) within the general population.
Methods
Our study included 10,067 men and 9,598 women in its final analysis. We assessed each individual's annual average exposure to five distinct air pollutants: PM2.5, PM10, NO2, SO2, and CO. Additionally, we measured serum concentrations of AFP, CEA, CA19-9, CA125, and PSA.
Results
After adjusting for potential confounding factors, we discovered noteworthy associations. Both men and women demonstrated a negative correlation between annual average exposure to SO2 and PM10 and AFP concentration (all P < 0.05). In men, after multivariate adjustment, exposure to CO, NO2, SO2, and PM10 showed negative correlations with CEA concentration (all P < 0.05). Furthermore, in men, exposure to CO, NO2, and PM10 exhibited positive associations with PSA concentration after multivariate adjustment (all P < 0.05). Among women, a similar multivariate analysis indicated that SO2 exposure was negatively correlated with CEA concentration (all P < 0.05).
Conclusions
Our study presents the first evidence of a potential link between air pollution exposure and tumor markers within the general population. To establish the validity of these associations, further investigations employing prospective analyses are warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract